
## COVID Intake Flowchart with History, Physical Exam and Order Sheets

This document provides a decision tree, assessment sheet and order sheet to assist facilities receiving potential COVID-19 patients.

It should be clear that this document is based on current knowledge and supported by Level 3 (low quality evidence, expert opinion and consensus) evidence.

Every facility is different, and the evidence is changing. Use your professional experience and judgement when considering this document's applicability to your environment. For that purpose, the document is editable and can be changed to match your needs.

Source: <a href="https://www.ceep.ca/2019-ncov">https://www.ceep.ca/2019-ncov</a>



- (1) Ventilatory support should ideally be via ETT and initiated using protected intubation technique.
  - Consider ventilator settings with increased, FIO2, increased PEEP (15 cm H2O) and decreased Tidal Volume (4-8ml/kg).
  - The shift to prone positioning, if indicated, should occur in the definitive treatment area, not the ED.
  - If a ventilator is unavailable, consider CPAP at 10cm H2O PEEP and FiO2 50%-60% using aerosol precautions in dedicated isolated area and with dedicated staff in appropriate PPE.

This chart is to assist with decisions on discharge, admission & ventilatory support in suspected COVID patients. Other aspects of care and, possibly confounding, medical conditions should always be considered & treated.

## **COVID-19 Nonacute – Assessment Form**

Date of symptom onset:	
Date of COVID test:	□ N/A

Modified with thanks from a document by the Nova Scotia Health Authority

Allergies:	PUBLIC HEALTH CONTRAINDICATION(S) TO DISCHARG  — Homeless, or no access to food, water, safe shelter or communicate
HPI:  Cough/Sore throat Shortness of breath Fever Chest pain Diarrhea Nausea/vomiting Anosmia/ Dysgeusia Rhinorrhea	□ Lives with a high-risk individual without ability to self-isolate in h
PMH:  ☐ Age 65+ years ☐ Chronic Pulmonary Disease ☐ Smoking history (current) ☐ Immunosuppression ☐ Diabetes mellitus ☐ Chronic Heart Disease ☐ Neurodegenerative Disorder ☐ Pregnancy ☐ Significant medical comorbidity	
PHYSICAL EXAM: Time  BP HR RR  SpO <sub>2</sub> % ( R/A or L O <sub>2</sub> SpO2 post walk test % Ca appearance:	Temp
SpO2 post walk test% ☐ Ca  DISPOSITION/PLAN: ☐ Discharge home ☐ Discharge	Temp SpO <sub>2</sub> % ( R/A or L O <sub>2</sub> ) annot walk (new since arrival)  the home with follow-up: thing Physician ublic health contraindications to discharge
	Date (yyyy/mm/dd): Time: Reg. No.:

## **COVID-19 Nonacute - Orders**

Allergies:		

Modified with thanks from a document by the Nova Scotia **Health Authority** 

Orders marked with a • should be initiated by RN's without awaiting MD
--

	Orders marked	with a • should be initiated by RN's with	out awaiting MD	
• App • Avo • Obta • Place • Nasa - 1 - 1 - 1  • If res   MEDI	ain vital signs (HR, BP, RR, Sp02, Te e a large bore peripheral IV cannula (al cannula 1-5L/min for target SpO2: greater than or equal to 90% (non-probetween 92-95% (pregnant) 88-92% (if known CO2-retainer) spiratory deterioration or rapid increa BP is less than 95mmHg, administer:  NS bolus of 10ml/kg over 15 mi bolus ofmls over CATIONS:	egnant) se in FIO2 advise MD nutes	□ Palliative care only □ Other − (Specify below)  DIAGNOSTIC INVESTIGATIONS:  • Confirmatory COVID-19 NPS if not already done □ Chest x-ray □ Portable □ ECG □ Creatinine; urea □ CBC, auto diff, PTT; INR □ Lytes (Na, K), glucose □ CK; Troponin □ ALP □ Procalcitonin □ B-HCG (women childbearing age)	
	Indication	Salbutamal 100 mag MDI   spagar	Investigation 20 mag MDI I spaces	
	Indication  Rapid reversal of airflow limitation (e.g., acute asthma or severe COPD exacerbation)	4 to 10 puffs inh q20min x 3 doses, then 4 to 10 puffs inh q3-4h (up to 10 puffs q1h) <sup>1</sup>	Ipratropium 20 mcg MDI + spacer  4 to 8 puffs inh q20min prn for up to 3h <sup>2</sup>	
	Dyspnea and/or reversal of bronchoconstriction (e.g., patient with pneumonia)	2 to 4 puffs inh q4h prn	2 to 4 puffs inh q4h prn	
	For as needed symptoms (e.g., as a supplement to LABA and/or LAMA)	2 to 4 puffs inh q4h prn (up to q1h prn)	2 to 4 puffs inh q4h prn (up to q1h prn)	
	COPD exacerbation <sup>3</sup>	2 puffs inh q1h x 3 doses, then 2 to 4 puffs inh q2-4h prn	2 puffs inh q1h x 3 doses, then 2 to 4 puffs inh q2-4h	
	COPD maintenance <sup>4</sup> (e.g., in place of LAMA and/or LABA)	2 puffs inh q6h prn	2 puffs inh q6h	
Other  Rea	If Penicillin allergy: □ Doxycyclin  Orders:  ssess in 6 hours with walk test and do		cin 750 mg PO daily x 5 days	
Prescriber's Signature:		Date (yyyy/mm/dd): Reg. No :	Time:	